Medtronic plc (MDT) Stock Forecast
Data as of Jul 31, 2026Healthcare · Current price $85.79 (+0.09%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 15, 2026 | Richard Newitter | Truist Financial | $95.00 | +10.7% |
| Apr 9, 2026 | Vijay Kumar | Evercore ISI | $106.00 | +23.6% |
| Mar 10, 2026 | Mike Kratky | Leerink Partners | $119.00 | +38.7% |
| Mar 10, 2026 | Michael Matson | Needham | $120.00 | +39.9% |
| Feb 18, 2026 | Matt Miksic | Barclays | $118.00 | +37.5% |
| Jan 30, 2026 | Larry Biegelsen | Wells Fargo | $114.00 | +32.9% |
| Jan 8, 2026 | Matt Miksic | Barclays | $116.00 | +35.2% |
| Dec 18, 2025 | Richard Newitter | Truist Financial | $107.00 | +24.7% |
| Nov 19, 2025 | Lee Hambright | Bernstein | $111.00 | +29.4% |
| Nov 19, 2025 | Mike Kratky | Leerink Partners | $120.00 | +39.9% |
| Nov 19, 2025 | Matthew Taylor | Jefferies | $110.00 | +28.2% |
| Nov 19, 2025 | David Roman | Goldman Sachs | $111.00 | +29.4% |
| Oct 31, 2025 | Lee Hambright | Bernstein | $98.00 | +14.2% |
| Aug 26, 2025 | David Toung | Argus Research | $115.00 | +34.0% |
| Jan 8, 2025 | Lee Hambright | Bernstein | $93.00 | +8.4% |
| Oct 15, 2024 | David Rescott | Robert W. Baird | $96.00 | +11.9% |
| Oct 10, 2024 | Shagun Singh | RBC Capital | $105.00 | +22.4% |
| Oct 1, 2024 | Vijay Kumar | Evercore ISI | $104.00 | +21.2% |
| Oct 1, 2024 | Joanne Wuensch | Citigroup | $92.00 | +7.2% |
| Aug 21, 2024 | David Roman | Goldman Sachs | $82.00 | -4.4% |
Top Analysts Covering MDT
MDT vs Sector & Market
| Metric | MDT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.28 | 2.25 | 2.42 |
| Analyst Count | 32 | 8 | 19 |
| Target Upside | +15.2% | +16366.1% | +18.0% |
| P/E Ratio | 23.00 | 2.99 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-10-23 | $9.03B | $9.43B | $9.73B | 7 |
| 2027-01-23 | $9.04B | $9.44B | $9.73B | 11 |
| 2027-04-23 | $9.63B | $10.06B | $10.37B | 11 |
| 2027-04-30 | $37.59B | $38.41B | $39.09B | 21 |
| 2027-07-23 | $9.28B | $9.69B | $9.99B | 11 |
| 2027-10-23 | $9.54B | $9.96B | $10.27B | 11 |
| 2028-01-23 | $9.62B | $10.04B | $10.35B | 5 |
| 2028-04-23 | $10.26B | $10.72B | $11.05B | 5 |
| 2028-04-30 | $40.09B | $40.17B | $40.25B | 23 |
| 2029-04-30 | $40.80B | $42.13B | $42.84B | 14 |
| 2030-04-30 | $43.07B | $44.48B | $45.22B | 11 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-10-23 | $1.35 | $1.43 | $1.49 | 12 |
| 2027-01-23 | $1.39 | $1.47 | $1.53 | 12 |
| 2027-04-23 | $1.68 | $1.78 | $1.85 | 6 |
| 2027-04-30 | $5.99 | $6.08 | $6.24 | 16 |
| 2027-07-23 | $1.39 | $1.47 | $1.53 | 10 |
| 2027-10-23 | $1.47 | $1.55 | $1.61 | 6 |
| 2028-01-23 | $1.50 | $1.59 | $1.65 | 7 |
| 2028-04-23 | $1.80 | $1.91 | $1.98 | 9 |
| 2028-04-30 | $5.84 | $6.51 | $7.14 | 9 |
| 2029-04-30 | $6.82 | $7.11 | $7.27 | 3 |
| 2030-04-30 | $7.42 | $7.74 | $7.91 | 3 |
Frequently Asked Questions
What is the analyst consensus for MDT?
The consensus among 32 analysts covering Medtronic plc (MDT) is Buy with an average price target of $95.80.
What is the highest price target for MDT?
The highest price target for MDT is $165.00, set by David Toung at Argus Research on 2021-08-27.
What is the lowest price target for MDT?
The lowest price target for MDT is $80.00, set by Pito Chickering at Deutsche Bank on 2022-11-23.
How many analysts cover MDT?
32 analysts have issued ratings for Medtronic plc in the past 12 months.
Is MDT a buy or sell right now?
Based on 32 analyst ratings, MDT has a consensus rating of Buy (2.28/5) with a +15.2% upside to the consensus target of $95.80.
What are the earnings estimates for MDT?
Analysts estimate MDT will report EPS of $1.43 for the period ending 2026-10-23, with revenue estimated at $9.43B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.